Transaction #634 · Form 4 · 0001610717-25-000361
Revolution Medicines, Inc. · Exercise / conversion · Common Stock
Revolution Medicines, Inc. · Transacted October 13, 2025 · Filed October 15, 2025
What does this filing report?
An SEC Form 4 filing for Revolution Medicines, Inc. records an exercise / conversion involving Common Stock on October 13, 2025. The reported quantity was 25,000. The filing date is October 15, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Revolution Medicines, Inc.
- Company CIK
- 0001628171
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 25,000
- Reported price
- 4.73
- Reference value
- 118,250
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 309,047
- Ownership description
- Not reported
- SEC acceptance time
- Oct 15, 2025, 5:09 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kelsey Stephen Michael ↗
See Remarks
CIK 0001462808
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
- F2
- Includes 84,000 restricted stock units.
- F3
- The transaction was executed in multiple trades in prices ranging from $48.03 to $48.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
President, Research and Development
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.